Also known as ELABELA · Toddler · APELA · ELA-32
The second endogenous ligand of the apelin receptor — a disulfide-bridged peptide required for heart development, studied in the adult cardiovascular system.
Research refreshed
66 residues · single-letter amino-acid sequence
Elabela (gene APELA, also called toddler) is a peptide hormone that activates the same receptor as apelin, APLNR. The human gene encodes a 54-residue precursor. The defined research peptide is ELA-32, residues 23–54 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP), with a disulfide between Cys17 and Cys22 of that fragment. Shorter processed forms (ELA-22/21 and ELA-11) are also described. It is not an approved medicine.
Elabela was found twice, under two names, as the ligand the apelin receptor had been missing in early embryos. Chng and colleagues (Developmental Cell, 2013) named the zebrafish gene elabela and showed it is required before apelin is expressed; Pauli and colleagues (Science, 2014) named the same signal toddler and showed it drives mesendodermal cell movement through the apelin receptor. The human precursor is UniProt P0DMC3. Proteolytic processing releases ELA-32 and shorter C-terminal fragments; ELA-32 is the species sold as a research peptide.
The developmental phenotype is the reason the peptide is in the literature. Loss of Apela in mice causes low-penetrance embryonic lethality and defects in early mesoderm (Freyer et al., Cell Reports 2017), and a separate mouse study tied ELABELA deficiency to preeclampsia-like disease and cardiovascular malformations (Ho et al., Science 2017). Those are genetic findings about the endogenous hormone, not evidence for administering the peptide.
In the adult, exogenous ELA-32 is an APLNR agonist in cardiovascular models. Yang and colleagues (Circulation, 2017) reported that elabela/toddler acts in the adult cardiovascular system and that giving the peptide offset a fall in its expression in a pulmonary-arterial-hypertension model. It binds APLNR differently from apelin (Couvineau et al., FASEB Journal 2020). No elabela product is FDA-approved, and the native fragments are research materials, not medicines.
Agonist at the class A GPCR APLNR, binding in a pose distinct from apelin. Coupling supports the same cardiovascular outputs studied for apelin — vasodilation and inotropy — and, in the embryo, the cell movements that build the heart. In human embryonic stem cells it has also been studied as a PI3K/AKT signal that supports self-renewal.
Behind every vial of Elabela is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Elabela, specifically, is brought into being.
On paper, Elabela is C170H289N63O39S4 — about 3,967.8 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Elabela is built one protected residue at a time by solid-phase synthesis, each cycle a deprotection, a coupling, and a wash. It also carries a disulfide bridge, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Elabela plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Elabela proves itself: identity confirmed by mass spectrometry against its ~3,967.8 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Elabela — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
ELA-32 is a 32-residue solid-phase synthesis with one intramolecular disulfide (Cys17–Cys22 of the fragment) and a free C-terminal acid. Chain length and the basic run of arginines and lysines make the assembly harder than apelin-13, and the disulfide has to be formed and confirmed as the intramolecular bridge rather than as dimers. The specification also has to name the fragment: the precursor (UniProt P0DMC3) is processed to 32-, 22-/21-, and 11-residue peptides, and those are not interchangeable. Two methionines are oxidation sites.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Elabela, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Elabela (also called toddler, gene APELA) is the second peptide that activates the apelin receptor. The research material is usually ELA-32, a 32-residue disulfide-bridged fragment of a 54-residue precursor.
Both agonize APLNR, but they are different genes and different sequences, and they bind the receptor differently. Elabela is the ligand the embryo uses before apelin is expressed. Apelin-13 has no disulfide; ELA-32 has one.
No. The published work is genetic and preclinical. No elabela product is FDA-approved.
No — this is a research and educational reference, not dosing guidance.
Once-weekly GLP-1 receptor agonist built as an Fc-fusion protein (Trulicity) — FDA-approved for type 2 diabetes since 2014, with cardiovascular-outcomes data from REWIND.
ViewThe first GLP-1 receptor agonist ever approved (Byetta, 2005) — synthetic exendin-4, a 39-residue peptide first isolated from Gila monster venom.
ViewThe archetypal protein biologic — a 51-amino-acid two-chain hormone, disulfide-linked, and the first recombinant DNA drug ever marketed.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.